Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
WALTHAM, Mass., Jan. 26, 2016 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday February 9, 2016 at 3:30PM EST during the conference’s Regenerative Medicine track at the Waldorf Astoria in New York, NY. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be available on Histogenics’ website for 30 days following the conference.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
